{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:09:17Z","timestamp":1789142957844,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13016-9","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T10:01:45Z","timestamp":1728554505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study"],"prefix":"10.1186","volume":"24","author":[{"given":"Jinbo","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoke","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leihong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"issue":"1","key":"13016_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"13016_CR2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.medcli.2017.06.009","volume":"149","author":"RR Martinez","year":"2017","unstructured":"Martinez RR, Buisan RO, Ibarz L. Bladder cancer: Present and future. Med Clin (Barc). 2017;149(10):449\u201355.","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"13016_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol. 2023;84(2):191\u2013206.","journal-title":"Eur Urol"},{"issue":"6","key":"13016_CR4","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.euf.2020.06.024","volume":"7","author":"H Harrison","year":"2021","unstructured":"Harrison H, et al. Risk Prediction Models for Kidney Cancer: A Systematic Review. Eur Urol Focus. 2021;7(6):1380\u201390.","journal-title":"Eur Urol Focus"},{"key":"13016_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s12935-020-01590-4","volume":"20","author":"Y Huang","year":"2020","unstructured":"Huang Y, et al. Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis. Cancer Cell Int. 2020;20:499.","journal-title":"Cancer Cell Int"},{"key":"13016_CR6","doi-asserted-by":"crossref","unstructured":"Catalano M, et al. Inflammation in Urological Malignancies: The Silent Killer. Int J Mol Sci. 2023;24(1):866.","DOI":"10.3390\/ijms24010866"},{"issue":"4","key":"13016_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19(4):237\u201353.","journal-title":"Nat Rev Clin Oncol."},{"issue":"36","key":"13016_CR8","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.2174\/0929867324666170712160621","volume":"25","author":"NC Kampan","year":"2018","unstructured":"Kampan NC, et al. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities. Curr Med Chem. 2018;25(36):4785\u2013806.","journal-title":"Curr Med Chem"},{"issue":"1","key":"13016_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12885-019-5353-6","volume":"19","author":"CR Goulet","year":"2019","unstructured":"Goulet CR, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC Cancer. 2019;19(1):137.","journal-title":"BMC Cancer"},{"issue":"6","key":"13016_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.14740\/wjon1536","volume":"13","author":"SM Warli","year":"2022","unstructured":"Warli SM, et al. Association Between Interleukin-6 Levels and Lymph Node Metastasis in Bladder Cancer Patients. World J Oncol. 2022;13(6):365\u20139.","journal-title":"World J Oncol"},{"issue":"2","key":"13016_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/CBM-2009-0133","volume":"6","author":"MA Mahmoud","year":"2010","unstructured":"Mahmoud MA, et al. Serum interleukin-8 and insulin like growth factor-1 in Egyptian bladder cancer patients. Cancer Biomark. 2010;6(2):105\u201310.","journal-title":"Cancer Biomark"},{"key":"13016_CR12","doi-asserted-by":"crossref","unstructured":"Xu Y, et al. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. J Immunother Cancer. 2022;10(3):e003416.","DOI":"10.1136\/jitc-2021-003416"},{"issue":"16","key":"13016_CR13","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2000.18.16.2963","volume":"18","author":"K Gohji","year":"2000","unstructured":"Gohji K, et al. Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J Clin Oncol. 2000;18(16):2963\u201371.","journal-title":"J Clin Oncol"},{"key":"13016_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155112","volume":"131","author":"CH Chen","year":"2020","unstructured":"Chen CH, et al. Association between VEGF gene promoter polymorphisms and bladder cancer: An updated meta-analysis. Cytokine. 2020;131: 155112.","journal-title":"Cytokine"},{"issue":"1","key":"13016_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12865-020-00396-3","volume":"22","author":"W Xiu","year":"2021","unstructured":"Xiu W, Luo J. CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling. BMC Immunol. 2021;22(1):3.","journal-title":"BMC Immunol"},{"issue":"1","key":"13016_CR16","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1186\/s12885-020-07548-z","volume":"20","author":"A John","year":"2020","unstructured":"John A, et al. Bladder cancer-derived interleukin-1 converts the vascular endothelium into a pro-inflammatory and pro-coagulatory surface. BMC Cancer. 2020;20(1):1178.","journal-title":"BMC Cancer"},{"issue":"1","key":"13016_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12865-016-0174-8","volume":"17","author":"Y Liu","year":"2016","unstructured":"Liu Y, et al. Immune analysis of expression of IL-17 relative ligands and their receptors in bladder cancer: comparison with polyp and cystitis. BMC Immunol. 2016;17(1):36.","journal-title":"BMC Immunol"},{"issue":"19","key":"13016_CR18","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. JAMA. 2017;318(19):1925\u20136.","journal-title":"JAMA"},{"issue":"1","key":"13016_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ajhg.2016.11.007","volume":"100","author":"AV Ahola-Olli","year":"2017","unstructured":"Ahola-Olli AV, et al. Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. Am J Hum Genet. 2017;100(1):40\u201350.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"13016_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/jmedgenet-2018-105965","volume":"56","author":"E Sliz","year":"2019","unstructured":"Sliz E, et al. Genome-wide association study identifies seven novel loci associating with circulating cytokines and cell adhesion molecules in Finns. J Med Genet. 2019;56(9):607\u201316.","journal-title":"J Med Genet"},{"issue":"3","key":"13016_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/ije\/dyr036","volume":"40","author":"S Burgess","year":"2011","unstructured":"Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755\u201364.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"13016_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jrsm.1346","volume":"10","author":"J Bowden","year":"2019","unstructured":"Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: A review. Res Synth Methods. 2019;10(4):486\u201396.","journal-title":"Res Synth Methods"},{"issue":"7","key":"13016_CR23","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/gepi.21758","volume":"37","author":"S Burgess","year":"2013","unstructured":"Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658\u201365.","journal-title":"Genet Epidemiol"},{"key":"13016_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.1","volume":"4","author":"S Burgess","year":"2019","unstructured":"Burgess S, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2019;4:186.","journal-title":"Wellcome Open Res"},{"issue":"1","key":"13016_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/EDE.0000000000000559","volume":"28","author":"S Burgess","year":"2017","unstructured":"Burgess S, et al. Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. Epidemiology. 2017;28(1):30\u201342.","journal-title":"Epidemiology"},{"issue":"2","key":"13016_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey SG, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512\u201325.","journal-title":"Int J Epidemiol"},{"issue":"5","key":"13016_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693\u20138.","journal-title":"Nat Genet"},{"issue":"3","key":"13016_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/ng.3211","volume":"47","author":"BK Bulik-Sullivan","year":"2015","unstructured":"Bulik-Sullivan BK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47(3):291\u20135.","journal-title":"Nat Genet"},{"issue":"5","key":"13016_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"Giambartolomei C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10(5): e1004383.","journal-title":"PLoS Genet"},{"issue":"4","key":"13016_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/aje\/kwu283","volume":"181","author":"S Burgess","year":"2015","unstructured":"Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015;181(4):251\u201360.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"13016_CR31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41588-018-0309-3","volume":"51","author":"LR Karlsson","year":"2019","unstructured":"Karlsson LR, et al. Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. Nat Genet. 2019;51(2):245\u201357.","journal-title":"Nat Genet"},{"issue":"20","key":"13016_CR32","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1093\/hmg\/ddy271","volume":"27","author":"L Yengo","year":"2018","unstructured":"Yengo L, et al. Meta-analysis of genome-wide association studies for height and body mass index in approximately 700000 individuals of European ancestry. Hum Mol Genet. 2018;27(20):3641\u20139.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"13016_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12916-023-02736-7","volume":"21","author":"B Liu","year":"2023","unstructured":"Liu B, et al. Associations of the circulating levels of cytokines with risk of amyotrophic lateral sclerosis: a Mendelian randomization study. BMC Med. 2023;21(1):39.","journal-title":"BMC Med"},{"issue":"12","key":"13016_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007149","volume":"13","author":"G Hemani","year":"2017","unstructured":"Hemani G, Tilling K, Davey SG. Correction: Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13(12): e1007149.","journal-title":"PLoS Genet"},{"issue":"5","key":"13016_CR35","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/ije\/dyt179","volume":"42","author":"MJ Brion","year":"2013","unstructured":"Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013;42(5):1497\u2013501.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"13016_CR36","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/ije\/dyx034","volume":"46","author":"OO Yavorska","year":"2017","unstructured":"Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734\u20139.","journal-title":"Int J Epidemiol"},{"key":"13016_CR37","doi-asserted-by":"crossref","unstructured":"Hemani G, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.","DOI":"10.7554\/eLife.34408"},{"key":"13016_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cca.2018.01.039","volume":"480","author":"Y Lin","year":"2018","unstructured":"Lin Y, et al. Association between obesity and bladder cancer recurrence: A meta-analysis. Clin Chim Acta. 2018;480:41\u20136.","journal-title":"Clin Chim Acta"},{"issue":"20","key":"13016_CR39","doi-asserted-by":"publisher","first-page":"20459","DOI":"10.1002\/cam4.6620","volume":"12","author":"M van Zutphen","year":"2023","unstructured":"van Zutphen M, et al. Body mass index and waist circumference in relation to risk of recurrence and progression after non-muscle invasive bladder cancer. Cancer Med. 2023;12(20):20459\u201369.","journal-title":"Cancer Med"},{"issue":"2","key":"13016_CR40","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jaci.2020.05.044","volume":"147","author":"C Li","year":"2021","unstructured":"Li C, et al. Psoriasis-associated impairment of CCL27\/CCR10-derived regulation leads to IL-17A\/IL-22-producing skin T-cell overactivation. J Allergy Clin Immunol. 2021;147(2):759-763.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"13016_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-030-36667-4_3","volume":"1231","author":"N Mukaida","year":"2020","unstructured":"Mukaida N, Sasaki SI, Baba T. CCL4 Signaling in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1231:23\u201332.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"13016_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12885-017-3718-2","volume":"18","author":"MJ Mao","year":"2018","unstructured":"Mao MJ, et al. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population. BMC Cancer. 2018;18(1):9.","journal-title":"BMC Cancer"},{"key":"13016_CR43","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.intimp.2017.07.018","volume":"51","author":"HY Lin","year":"2017","unstructured":"Lin HY, et al. CCR10 activation stimulates the invasion and migration of breast cancer cells through the ERK1\/2\/MMP-7 signaling pathway. Int Immunopharmacol. 2017;51:124\u201330.","journal-title":"Int Immunopharmacol"},{"issue":"48","key":"13016_CR44","doi-asserted-by":"publisher","first-page":"78605","DOI":"10.18632\/oncotarget.12522","volume":"7","author":"S Thangavadivel","year":"2016","unstructured":"Thangavadivel S, et al. CCR10\/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. Oncotarget. 2016;7(48):78605\u201318.","journal-title":"Oncotarget"},{"issue":"8","key":"13016_CR45","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13238-012-2927-3","volume":"3","author":"N Xiong","year":"2012","unstructured":"Xiong N, et al. CCR10 and its ligands in regulation of epithelial immunity and diseases. Protein Cell. 2012;3(8):571\u201380.","journal-title":"Protein Cell"},{"issue":"11","key":"13016_CR46","first-page":"13135","volume":"13","author":"Y Liu","year":"2021","unstructured":"Liu Y, Xiao A, Zhang B. CCR10\/CCL27 crosstalk regulates cell metastasis via PI3K-Akt signaling axis in non-small-cell lung cancer. Am J Transl Res. 2021;13(11):13135\u201346.","journal-title":"Am J Transl Res"},{"issue":"3","key":"13016_CR47","first-page":"349","volume":"38","author":"B Li","year":"2023","unstructured":"Li B, et al. The CCL27-CCR10 axis contributes to promoting proliferation, migration, and invasion of lung squamous cell carcinoma. Histol Histopathol. 2023;38(3):349\u201357.","journal-title":"Histol Histopathol"},{"issue":"1","key":"13016_CR48","doi-asserted-by":"publisher","first-page":"1776060","DOI":"10.1080\/2162402X.2020.1776060","volume":"9","author":"W Zhong","year":"2020","unstructured":"Zhong W, et al. Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer. Oncoimmunology. 2020;9(1):1776060.","journal-title":"Oncoimmunology"},{"issue":"1","key":"13016_CR49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12894-021-00938-w","volume":"21","author":"Y Li","year":"2021","unstructured":"Li Y, et al. Identification of prognostic and therapeutic value of CC chemokines in Urothelial bladder cancer: evidence from comprehensive bioinformatic analysis. BMC Urol. 2021;21(1):173.","journal-title":"BMC Urol"},{"key":"13016_CR50","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2022.28","volume":"24","author":"TE Mergia","year":"2022","unstructured":"Mergia TE, et al. Roles of CCR10\/CCL27-CCL28 axis in tumour development: mechanisms, diagnostic and therapeutic approaches, and perspectives. Expert Rev Mol Med. 2022;24: e37.","journal-title":"Expert Rev Mol Med"},{"issue":"1","key":"13016_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41467-023-44310-y","volume":"15","author":"E Landoni","year":"2024","unstructured":"Landoni E, et al. IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat Commun. 2024;15(1):89.","journal-title":"Nat Commun"},{"issue":"3","key":"13016_CR52","first-page":"131","volume":"7","author":"T Nishimura","year":"1994","unstructured":"Nishimura T, et al. An efficient methods for the induction of human antitumor effector CD4+ and CD8+ T cells: their application to tumor immunotherapy. Hum Cell. 1994;7(3):131\u20137.","journal-title":"Hum Cell"},{"key":"13016_CR53","doi-asserted-by":"crossref","unstructured":"Wolacewicz M, et al. Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. Cancers (Basel). 2020;12(5):1181.","DOI":"10.3390\/cancers12051181"},{"issue":"1","key":"13016_CR54","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1365-2249.2002.01734.x","volume":"127","author":"J Riemensberger","year":"2002","unstructured":"Riemensberger J, Bohle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol. 2002;127(1):20\u20136.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"13016_CR55","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.urology.2005.03.052","volume":"66","author":"M Horinaga","year":"2005","unstructured":"Horinaga M, et al. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology. 2005;66(2):461\u20136.","journal-title":"Urology"},{"issue":"3","key":"13016_CR56","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1097\/01.ju.0000109742.88380.a2","volume":"171","author":"MA O'Donnell","year":"2004","unstructured":"O\u2019Donnell MA, et al. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. J Urol. 2004;171(3):1330\u20135.","journal-title":"J Urol"},{"issue":"7","key":"13016_CR57","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard JP, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90(7):2541\u20138.","journal-title":"Blood"},{"issue":"6","key":"13016_CR58","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-015-1672-x","volume":"64","author":"SG Smith","year":"2015","unstructured":"Smith SG, et al. Intravesical chitosan\/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer. Cancer Immunol Immunother. 2015;64(6):689\u201396.","journal-title":"Cancer Immunol Immunother"},{"issue":"15","key":"13016_CR59","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1158\/0008-5472.CAN-09-1114","volume":"69","author":"DA Zaharoff","year":"2009","unstructured":"Zaharoff DA, et al. Intravesical immunotherapy of superficial bladder cancer with chitosan\/interleukin-12. Cancer Res. 2009;69(15):6192\u20139.","journal-title":"Cancer Res"},{"key":"13016_CR60","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/ITT.S306150","volume":"10","author":"JW Greiner","year":"2021","unstructured":"Greiner JW, Morillon YN, Schlom J. NHS-IL12, a Tumor-Targeting Immunocytokine. Immunotargets Ther. 2021;10:155\u201369.","journal-title":"Immunotargets Ther"},{"issue":"1","key":"13016_CR61","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s40425-019-0620-2","volume":"7","author":"YN Morillon","year":"2019","unstructured":"Morillon YN, et al. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12. J Immunother Cancer. 2019;7(1):150.","journal-title":"J Immunother Cancer"},{"issue":"13","key":"13016_CR62","doi-asserted-by":"publisher","first-page":"20558","DOI":"10.18632\/oncotarget.16137","volume":"8","author":"JK Fallon","year":"2017","unstructured":"Fallon JK, et al. Enhanced antitumor effects by combining an IL-12\/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. Oncotarget. 2017;8(13):20558\u201371.","journal-title":"Oncotarget"},{"issue":"39","key":"13016_CR63","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1016\/j.vaccine.2009.06.079","volume":"27","author":"YS Tsai","year":"2009","unstructured":"Tsai YS, et al. Enhancement of antitumor immune response by targeted interleukin-12 electrogene transfer through antiHER2 single-chain antibody in a murine bladder tumor model. Vaccine. 2009;27(39):5383\u201392.","journal-title":"Vaccine"},{"issue":"1","key":"13016_CR64","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.gene.2013.01.025","volume":"519","author":"PK Jaiswal","year":"2013","unstructured":"Jaiswal PK, et al. Association of IL-12, IL-18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population. Gene. 2013;519(1):128\u201334.","journal-title":"Gene."},{"key":"13016_CR65","doi-asserted-by":"crossref","unstructured":"Strauss J, et al. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. J Immunother Cancer. 2023;11(5):e005813.","DOI":"10.1136\/jitc-2022-005813"},{"key":"13016_CR66","doi-asserted-by":"crossref","unstructured":"Bui QT, et al, Disruption of CCL2 in Mesenchymal Stem Cells as an Anti-Tumor Approach against Prostate Cancer. Cancers (Basel). 2023;15(2):441.","DOI":"10.3390\/cancers15020441"},{"key":"13016_CR67","doi-asserted-by":"crossref","unstructured":"Iwamoto H, et al. Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer. Biomedicines. 2022;10(10):2369.","DOI":"10.3390\/biomedicines10102369"},{"issue":"5","key":"13016_CR68","doi-asserted-by":"publisher","first-page":"238.e19","DOI":"10.1016\/j.urolonc.2015.11.026","volume":"34","author":"Y Yang","year":"2016","unstructured":"Yang Y, et al. High expression of chemokine CCL2 is associated with recurrence after surgery in clear-cell renal cell carcinoma. Urol Oncol. 2016;34(5):238.e19-26.","journal-title":"Urol Oncol."},{"issue":"32","key":"13016_CR69","doi-asserted-by":"publisher","first-page":"51525","DOI":"10.18632\/oncotarget.10492","volume":"7","author":"Z Wang","year":"2016","unstructured":"Wang Z, et al. CCL2\/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget. 2016;7(32):51525\u201334.","journal-title":"Oncotarget."},{"issue":"16","key":"13016_CR70","doi-asserted-by":"publisher","first-page":"6642","DOI":"10.18632\/aging.204236","volume":"14","author":"L Ma","year":"2022","unstructured":"Ma L, et al. Rhein promotes TRAIL-induced apoptosis in bladder cancer cells by up-regulating DR5 expression. Aging (Albany NY). 2022;14(16):6642\u201355.","journal-title":"Aging (Albany NY)."},{"issue":"8","key":"13016_CR71","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/CAD.0000000000000116","volume":"25","author":"T Zhang","year":"2014","unstructured":"Zhang T, et al. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR\/S6K1-mediated downregulation of c-FLIP. Anticancer Drugs. 2014;25(8):887\u201397.","journal-title":"Anticancer Drugs."},{"issue":"1","key":"13016_CR72","doi-asserted-by":"publisher","first-page":"1747332","DOI":"10.1080\/2162402X.2020.1747332","volume":"9","author":"Z Wang","year":"2020","unstructured":"Wang Z, et al. Tumor-infiltrating IL-17A(+) cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer. Oncoimmunology. 2020;9(1):1747332.","journal-title":"Oncoimmunology"},{"issue":"3","key":"13016_CR73","first-page":"1059","volume":"77","author":"FA Mousa","year":"2022","unstructured":"Mousa FA, Jasim HA, Shakir F. A Prognostic Impact of Interleukin 17 (IL-17) as an Immune-Marker in Patients with Bladder Cancer. Arch Razi Inst. 2022;77(3):1059\u201365.","journal-title":"Arch Razi Inst."},{"key":"13016_CR74","doi-asserted-by":"crossref","unstructured":"Mikkola T, et al. Variable roles of interleukin-17F in different cancers. BMC Cancer. 2022;22(1):54.","DOI":"10.1186\/s12885-021-08969-0"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13016-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T21:02:31Z","timestamp":1728594151000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13016-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13016"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13016-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since all of these data were openly accessible, patient consent had been obtained by corresponding studies, and ethical approval was not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"1261"}}